scholarly journals Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips

2016 ◽  
Vol 5 (7) ◽  
pp. 1361-1372 ◽  
Author(s):  
Veronika I. Butvilovskaya ◽  
Sofya B. Popletaeva ◽  
Vladimir R. Chechetkin ◽  
Zhanna I. Zubtsova ◽  
Marya V. Tsybulskaya ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay

2009 ◽  
Vol 8 (4) ◽  
pp. 509-517 ◽  
Author(s):  
Hiromu Naruse ◽  
Noriko Ikawa ◽  
Kiyoshi Yamaguchi ◽  
Yusuke Nakamura ◽  
Masami Arai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lynch Syndrome ◽  
Cancer Patients ◽  
Splice Site ◽  
Colorectal Cancer Patients

scholarly journals DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients

2018 ◽  
Vol 8 (4) ◽  
pp. 45 ◽  
Author(s):  
Arsalan Amirfallah ◽  
Gizem Kocal ◽  
Olcun Unal ◽  
Hulya Ellidokuz ◽  
Ilhan Oztop ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Methylenetetrahydrofolate Reductase ◽  
Dihydropyrimidine Dehydrogenase ◽  
Predictive Biomarkers ◽  
Related Factors ◽  
Mthfr Polymorphisms ◽  
Hematopoietic Toxicity ◽  
Colorectal Cancer Patients

Fluoropyrimidine-based chemotherapy is extensively used for the treatment of solid cancers, including colorectal cancer. However, fluoropyrimidine-driven toxicities are a major problem in the management of the disease. The grade and type of the toxicities depend on demographic factors, but substantial inter-individual variation in fluoropyrimidine-related toxicity is partly explained by genetic factors. The aim of this study was to investigate the effect of dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), and methylenetetrahydrofolate reductase (MTHFR) polymorphisms in colorectal cancer patients. Eighty-five patients who were administered fluoropyrimidine-based treatment were included in the study. The DPYD, TYMS and MTHFR polymorphisms were scanned by a next generation Sequenom MassARRAY. Fluoropyrimidine toxicities were observed in 92% of all patients. The following polymorphisms were detected: DPYD 85T>C (29.4% heterozygote mutants, 7.1% homozygote mutants), DPYD IVS 14+1G>A (1.2% heterozygote mutants), TYMS 1494del TTAAAG (38.4% heterozygote mutants, 24.7% homozygote mutants), MTHFR 677C>T (43.5% heterozygote mutants, 9.4% homozygote mutants) and MTHFR 1298A>C (8.2% heterozygote mutants, 2.4% homozygote mutants). A statistically significant association was demonstrated between MTHFR 677C>T and fluoropyrimidine-related toxicity. Furthermore, MTHFR 1298A>C was associated with hematopoietic toxicity. MTHFR polymorphisms may be considered as related factors of fluoropyrimidine toxicity and may be useful as predictive biomarkers for the determination of the colorectal cancer patients who can receive the greatest benefit from fluoropyrimidine-based treatments.

Determination of reduced folates in tumor and adjacent mucosa of colorectal cancer patients using LC-MS/MS

2012 ◽  
Vol 27 (4) ◽  
pp. 487-495 ◽  
Author(s):  
Elisabeth Odin ◽  
Yvonne Wettergren ◽  
Göran Carlsson ◽  
Bengt Gustavsson
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Adjacent Mucosa ◽  
Colorectal Cancer Patients

scholarly journals Determination of VOCs in Surgical Resected Tissues from Colorectal Cancer Patients by Solid Phase Microextraction Coupled to Gas Chromatography–Mass Spectrometry

2021 ◽  
Vol 11 (15) ◽  
pp. 6910
Author(s):  
Nicoletta De Vietro ◽  
Antonella Maria Aresta ◽  
Arcangelo Picciariello ◽  
Maria Teresa Rotelli ◽  
Carlo Zambonin
Keyword(s):  
Colorectal Cancer ◽  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Cancer Patients ◽  
Solid Phase Microextraction ◽  
Solid Phase ◽  
Gas Chromatography Mass Spectrometry ◽  
Volatile Organic ◽  
Colorectal Cancer Patients

Early diagnosis of colorectal cancer is crucial to increase the survival rates of the patients and breath analysis represents a promising non-invasive tool to obtain information on cancer-related variations on the human volatilome. A solid phase microextraction coupled to gas chromatography–mass spectrometry method for the determination of seven selected compounds, representative of the volatilome secreted by the colonic mucosa of patients affected by colorectal cancer, including benzaldehyde, benzoic acid, dodecane, ethylbenzene, octanal, tetradecane and toluene, was developed. All the extraction parameters were studied for both headspace and direct immersion sampling and the procedures fully validated. The potential of the approach was demonstrated by the time monitoring of the emission of the selected volatile organic compounds from the surgical resected colon mucosa tissues of colorectal cancer patients. Furthermore, the extraction and identification of thirty-one volatile organic compounds secreted by the same tissues was accomplished.

Sign in / Sign up

Export Citation Format

Share Document